KR850002285A - 면역 인터페론의 제조방법 - Google Patents
면역 인터페론의 제조방법 Download PDFInfo
- Publication number
- KR850002285A KR850002285A KR1019840005714A KR840005714A KR850002285A KR 850002285 A KR850002285 A KR 850002285A KR 1019840005714 A KR1019840005714 A KR 1019840005714A KR 840005714 A KR840005714 A KR 840005714A KR 850002285 A KR850002285 A KR 850002285A
- Authority
- KR
- South Korea
- Prior art keywords
- lys
- ser
- asp
- asn
- phe
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 7
- 102000008070 Interferon-gamma Human genes 0.000 title 1
- 108010074328 Interferon-gamma Proteins 0.000 title 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 5
- 244000005700 microbiome Species 0.000 claims 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 3
- 229960004198 guanidine Drugs 0.000 claims 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 3
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- GSCLWXDNIMNIJE-ZLUOBGJFSA-N Ala-Asp-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GSCLWXDNIMNIJE-ZLUOBGJFSA-N 0.000 claims 1
- BTBUEVAGZCKULD-XPUUQOCRSA-N Ala-Gly-His Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BTBUEVAGZCKULD-XPUUQOCRSA-N 0.000 claims 1
- YYAVDNKUWLAFCV-ACZMJKKPSA-N Ala-Ser-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYAVDNKUWLAFCV-ACZMJKKPSA-N 0.000 claims 1
- HQIZDMIGUJOSNI-IUCAKERBSA-N Arg-Gly-Arg Chemical compound N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQIZDMIGUJOSNI-IUCAKERBSA-N 0.000 claims 1
- BNYNOWJESJJIOI-XUXIUFHCSA-N Arg-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N BNYNOWJESJJIOI-XUXIUFHCSA-N 0.000 claims 1
- VRTWYUYCJGNFES-CIUDSAMLSA-N Arg-Ser-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O VRTWYUYCJGNFES-CIUDSAMLSA-N 0.000 claims 1
- YVXRYLVELQYAEQ-SRVKXCTJSA-N Asn-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N YVXRYLVELQYAEQ-SRVKXCTJSA-N 0.000 claims 1
- LMIWYCWRJVMAIQ-NHCYSSNCSA-N Asn-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N LMIWYCWRJVMAIQ-NHCYSSNCSA-N 0.000 claims 1
- SVFOIXMRMLROHO-SRVKXCTJSA-N Asp-Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SVFOIXMRMLROHO-SRVKXCTJSA-N 0.000 claims 1
- DXQOQMCLWWADMU-ACZMJKKPSA-N Asp-Gln-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O DXQOQMCLWWADMU-ACZMJKKPSA-N 0.000 claims 1
- CLUMZOKVGUWUFD-CIUDSAMLSA-N Asp-Leu-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O CLUMZOKVGUWUFD-CIUDSAMLSA-N 0.000 claims 1
- JIZRUFJGHPIYPS-SRVKXCTJSA-N Cys-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)O JIZRUFJGHPIYPS-SRVKXCTJSA-N 0.000 claims 1
- JFSNBQJNDMXMQF-XHNCKOQMSA-N Gln-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N)C(=O)O JFSNBQJNDMXMQF-XHNCKOQMSA-N 0.000 claims 1
- FFVXLVGUJBCKRX-UKJIMTQDSA-N Gln-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)N)N FFVXLVGUJBCKRX-UKJIMTQDSA-N 0.000 claims 1
- LKDIBBOKUAASNP-FXQIFTODSA-N Glu-Ala-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LKDIBBOKUAASNP-FXQIFTODSA-N 0.000 claims 1
- GZWOBWMOMPFPCD-CIUDSAMLSA-N Glu-Asp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N GZWOBWMOMPFPCD-CIUDSAMLSA-N 0.000 claims 1
- ILWHFUZZCFYSKT-AVGNSLFASA-N Glu-Lys-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ILWHFUZZCFYSKT-AVGNSLFASA-N 0.000 claims 1
- MRWYPDWDZSLWJM-ACZMJKKPSA-N Glu-Ser-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O MRWYPDWDZSLWJM-ACZMJKKPSA-N 0.000 claims 1
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 claims 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 claims 1
- FIMNVXRZGUAGBI-AVGNSLFASA-N His-Glu-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FIMNVXRZGUAGBI-AVGNSLFASA-N 0.000 claims 1
- LKACSKJPTFSBHR-MNXVOIDGSA-N Ile-Gln-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N LKACSKJPTFSBHR-MNXVOIDGSA-N 0.000 claims 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 claims 1
- WXUOJXIGOPMDJM-SRVKXCTJSA-N Leu-Lys-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O WXUOJXIGOPMDJM-SRVKXCTJSA-N 0.000 claims 1
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 claims 1
- NFLFJGGKOHYZJF-BJDJZHNGSA-N Lys-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN NFLFJGGKOHYZJF-BJDJZHNGSA-N 0.000 claims 1
- SJNZALDHDUYDBU-IHRRRGAJSA-N Lys-Arg-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(O)=O SJNZALDHDUYDBU-IHRRRGAJSA-N 0.000 claims 1
- ZJWIXBZTAAJERF-IHRRRGAJSA-N Lys-Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZJWIXBZTAAJERF-IHRRRGAJSA-N 0.000 claims 1
- JHNOXVASMSXSNB-WEDXCCLWSA-N Lys-Thr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JHNOXVASMSXSNB-WEDXCCLWSA-N 0.000 claims 1
- ONGCSGVHCSAATF-CIUDSAMLSA-N Met-Ala-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O ONGCSGVHCSAATF-CIUDSAMLSA-N 0.000 claims 1
- RZJOHSFAEZBWLK-CIUDSAMLSA-N Met-Gln-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N RZJOHSFAEZBWLK-CIUDSAMLSA-N 0.000 claims 1
- CHDYFPCQVUOJEB-ULQDDVLXSA-N Met-Leu-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CHDYFPCQVUOJEB-ULQDDVLXSA-N 0.000 claims 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 claims 1
- KZRQONDKKJCAOL-DKIMLUQUSA-N Phe-Leu-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KZRQONDKKJCAOL-DKIMLUQUSA-N 0.000 claims 1
- RMKGXGPQIPLTFC-KKUMJFAQSA-N Phe-Lys-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O RMKGXGPQIPLTFC-KKUMJFAQSA-N 0.000 claims 1
- OQTDZEJJWWAGJT-KKUMJFAQSA-N Phe-Lys-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O OQTDZEJJWWAGJT-KKUMJFAQSA-N 0.000 claims 1
- DOXQMJCSSYZSNM-BZSNNMDCSA-N Phe-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O DOXQMJCSSYZSNM-BZSNNMDCSA-N 0.000 claims 1
- OWSLLRKCHLTUND-BZSNNMDCSA-N Phe-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OWSLLRKCHLTUND-BZSNNMDCSA-N 0.000 claims 1
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 claims 1
- SWSRFJZZMNLMLY-ZKWXMUAHSA-N Ser-Asp-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O SWSRFJZZMNLMLY-ZKWXMUAHSA-N 0.000 claims 1
- ZKBKUWQVDWWSRI-BZSNNMDCSA-N Ser-Phe-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKBKUWQVDWWSRI-BZSNNMDCSA-N 0.000 claims 1
- BEBVVQPDSHHWQL-NRPADANISA-N Ser-Val-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BEBVVQPDSHHWQL-NRPADANISA-N 0.000 claims 1
- ODRUTDLAONAVDV-IHRRRGAJSA-N Ser-Val-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ODRUTDLAONAVDV-IHRRRGAJSA-N 0.000 claims 1
- JVTHIXKSVYEWNI-JRQIVUDYSA-N Thr-Asn-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JVTHIXKSVYEWNI-JRQIVUDYSA-N 0.000 claims 1
- AHOLTQCAVBSUDP-PPCPHDFISA-N Thr-Ile-Lys Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O AHOLTQCAVBSUDP-PPCPHDFISA-N 0.000 claims 1
- HJXOFWKCWLHYIJ-SZMVWBNQSA-N Trp-Lys-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HJXOFWKCWLHYIJ-SZMVWBNQSA-N 0.000 claims 1
- BGFCXQXETBDEHP-BZSNNMDCSA-N Tyr-Phe-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O BGFCXQXETBDEHP-BZSNNMDCSA-N 0.000 claims 1
- GOPQNCQSXBJAII-ULQDDVLXSA-N Tyr-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N GOPQNCQSXBJAII-ULQDDVLXSA-N 0.000 claims 1
- XTAUQCGQFJQGEJ-NHCYSSNCSA-N Val-Gln-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N XTAUQCGQFJQGEJ-NHCYSSNCSA-N 0.000 claims 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 108010062796 arginyllysine Proteins 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 claims 1
- 108010018006 histidylserine Proteins 0.000 claims 1
- 108010047926 leucyl-lysyl-tyrosine Proteins 0.000 claims 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 claims 1
- 108010044348 lysyl-glutamyl-aspartic acid Proteins 0.000 claims 1
- 108010054155 lysyllysine Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 108700023046 methionyl-leucyl-phenylalanine Proteins 0.000 claims 1
- 108010012581 phenylalanylglutamate Proteins 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제3도는 CNBr처리후, 15K 및 18K rIFN－г의 C－말단 펩티드를 HPLC분리이다. 제4도는 18K rIFN－г의 트립신 분해 펩티드지도이다.
Claims (10)
- 형질 전환된 미생물로 부터 단백질 분해 효소 억제제로 온전한 재조합 인체 면역 인터페론을 추출하고, 추출한 인터페론을 모노크로날 항체를 사용하여 정제함을 특징으로 하여, 인터페론을 함유하는 형질 전환된 미생물로 부터 본래 그의 단백질 분해 단편이 없는 하기의 아미노산 서열을 갖는 온전한 재조합 인체 면역 인터페론을 제조하는 방법.
- Cys Tyr Cys Gln Asp Pro Tyr Val Lys Glu Ala Glu Asn Leu Lys Tyr Phe Asn Ala Gly His Ser Asp Val Ala Asp Asn Gly Thr Leu Phe Leu Ile Leu Lys Asn Trp Lys Glu Glu Ser Asp ArgLys Ile Met Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Phe Lys Asn Phe Lys Asp Asp Gln Ser Ile Gln Lys Ser Val Glu Thr Ile Lys Glu Asp Met Asn Val Lys Phe Phe Asn Ser Asn Lys Lys Lys Arg Asp Asp Phe Glu Lys Leu Thr Asn Tyr Ser Val Tyr Asp Leu Asn Val Gln Arg Lys Ala Ile His Glu Leu Ile Gln Vla Met Ala Glu Leu Ser Pro Ala All Lys Thr Gly Lys Arg Lys Arg Ser Gln Met Leu Phe Arg Gly Arg Gly Arg Arg Ala Ser Gln
- (상기 서열의 아미노 말단에 부가적인 메티오닌 잔기가 임의로 포함될 수 있다.)
- 제1항에 있어서, 단백질 분해 효소 억제제가 구아니디늄 염인 방법.
- 제1항에 있어서, 단백질 분해 효소 억제제가 구아니딘－HCl인 방법.
- 제2 또는 3항에 있어서 구아니디늄 염이 용액내에 존재하는 방법.
- 제1항에 있어서, 형질 전환된 미생물을 구아니딘－HCl의 용액에 현탁시키는 방법.
- 제5항에 있어서, 구아니딘－HCl용액의 농도가 최소한 약 4M인 방법.
- 제5 또는 6항에 있어서, 형질 전환된 미생물 g당 최소한 약 3배 용적의 구아니디늄의 용액을 사용하는 방법.
- ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53404083A | 1983-09-20 | 1983-09-20 | |
| US534040 | 1983-09-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR850002285A true KR850002285A (ko) | 1985-05-10 |
| KR940004544B1 KR940004544B1 (en) | 1994-05-25 |
Family
ID=24128473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR84005714A KR940004544B1 (en) | 1983-09-20 | 1984-09-19 | Immune interferon and method for its extraction and purification |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0138087B1 (ko) |
| JP (1) | JP2592441B2 (ko) |
| KR (1) | KR940004544B1 (ko) |
| AT (1) | ATE33842T1 (ko) |
| AU (1) | AU590712B2 (ko) |
| DE (1) | DE3470747D1 (ko) |
| DK (1) | DK162604C (ko) |
| ES (1) | ES8606886A1 (ko) |
| FI (1) | FI80293C (ko) |
| GB (1) | GB2146998B (ko) |
| GR (1) | GR80405B (ko) |
| HU (1) | HU196461B (ko) |
| IL (1) | IL72986A (ko) |
| MC (1) | MC1627A1 (ko) |
| NO (1) | NO161274C (ko) |
| NZ (1) | NZ209588A (ko) |
| PH (1) | PH23241A (ko) |
| PT (1) | PT79232B (ko) |
| ZA (1) | ZA846554B (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2164650A (en) * | 1984-09-25 | 1986-03-26 | Fujisawa Pharmaceutical Co | Process for production of y-interferon |
| GB8508340D0 (en) * | 1985-03-29 | 1985-05-09 | Creighton T E | Production of protein |
| DE19755960C1 (de) | 1997-12-16 | 1998-11-26 | Hoechst Ag | Verfahren zum Aufschluß von biologischem Material |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7404589A (nl) * | 1974-04-03 | 1975-10-07 | Stichting Rega V Z W | Werkwijze voor het stabiliseren van interferon. |
| DE3005897A1 (de) * | 1980-02-16 | 1981-09-03 | Hoechst Ag, 6000 Frankfurt | Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus |
| IL65475A0 (en) * | 1981-04-17 | 1982-07-30 | Meloy Lab | Production of immune interferon and its mrna |
| IL63327A (en) * | 1981-07-16 | 1985-11-29 | Yeda Res & Dev | Production of interferon beta1 and alpha-phage recombinants for its production in host bacteria |
| AU561343B2 (en) * | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| JPS58110548A (ja) * | 1981-12-24 | 1983-07-01 | Asahi Chem Ind Co Ltd | 新規な生理活性ペプチド |
| EP0088540A3 (en) * | 1982-02-22 | 1984-10-17 | Biogen, Inc. | Dna sequences, recombinant dna molecules and processes for producing human immune interferon-like polypeptides |
| IL68100A0 (en) * | 1982-03-24 | 1983-06-15 | Takeda Chemical Industries Ltd | Novel dna and use thereof |
| IL69851A0 (en) * | 1982-09-30 | 1983-12-30 | Japan Found Cancer | Novel dna and recombinant plasmid containing the same |
| WO1984002129A1 (en) * | 1982-11-22 | 1984-06-07 | Takeda Chemical Industries Ltd | Human immune interferon protein and process for its preparation |
| JPH0740925B2 (ja) * | 1983-03-14 | 1995-05-10 | 協和醗酵工業株式会社 | 新規ヒトインタ−フエロン−γポリペプチド |
| US4855238A (en) * | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
-
1984
- 1984-08-22 ZA ZA846554A patent/ZA846554B/xx unknown
- 1984-09-18 NZ NZ209588A patent/NZ209588A/xx unknown
- 1984-09-18 EP EP19840111130 patent/EP0138087B1/en not_active Expired
- 1984-09-18 GR GR80405A patent/GR80405B/el unknown
- 1984-09-18 AT AT84111130T patent/ATE33842T1/de not_active IP Right Cessation
- 1984-09-18 DE DE8484111130T patent/DE3470747D1/de not_active Expired
- 1984-09-18 IL IL72986A patent/IL72986A/xx not_active IP Right Cessation
- 1984-09-19 KR KR84005714A patent/KR940004544B1/ko not_active IP Right Cessation
- 1984-09-19 MC MC841728A patent/MC1627A1/xx unknown
- 1984-09-19 NO NO843750A patent/NO161274C/no unknown
- 1984-09-19 PT PT79232A patent/PT79232B/pt not_active IP Right Cessation
- 1984-09-19 GB GB08423748A patent/GB2146998B/en not_active Expired
- 1984-09-19 JP JP59196499A patent/JP2592441B2/ja not_active Expired - Lifetime
- 1984-09-19 ES ES536028A patent/ES8606886A1/es not_active Expired
- 1984-09-19 PH PH31245A patent/PH23241A/en unknown
- 1984-09-19 AU AU33301/84A patent/AU590712B2/en not_active Ceased
- 1984-09-19 HU HU843509A patent/HU196461B/hu not_active IP Right Cessation
- 1984-09-19 FI FI843669A patent/FI80293C/fi not_active IP Right Cessation
- 1984-09-19 DK DK447784A patent/DK162604C/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| GB2146998B (en) | 1987-10-07 |
| GR80405B (en) | 1985-01-21 |
| FI80293C (fi) | 1990-05-10 |
| AU3330184A (en) | 1985-03-28 |
| EP0138087A1 (en) | 1985-04-24 |
| DK162604C (da) | 1992-05-11 |
| DK162604B (da) | 1991-11-18 |
| HU196461B (en) | 1988-11-28 |
| NO161274B (no) | 1989-04-17 |
| JPS6169800A (ja) | 1986-04-10 |
| PH23241A (en) | 1989-06-06 |
| GB2146998A (en) | 1985-05-01 |
| HUT35289A (en) | 1985-06-28 |
| FI843669L (fi) | 1985-03-21 |
| IL72986A (en) | 1990-04-29 |
| FI843669A0 (fi) | 1984-09-19 |
| PT79232A (en) | 1984-10-01 |
| KR940004544B1 (en) | 1994-05-25 |
| DK447784D0 (da) | 1984-09-19 |
| ES8606886A1 (es) | 1986-05-16 |
| DK447784A (da) | 1985-03-21 |
| PT79232B (en) | 1986-11-18 |
| NO161274C (no) | 1989-07-26 |
| JP2592441B2 (ja) | 1997-03-19 |
| AU590712B2 (en) | 1989-11-16 |
| NO843750L (no) | 1985-03-21 |
| DE3470747D1 (en) | 1988-06-01 |
| MC1627A1 (fr) | 1985-09-26 |
| ZA846554B (en) | 1985-04-24 |
| IL72986A0 (en) | 1984-12-31 |
| EP0138087B1 (en) | 1988-04-27 |
| NZ209588A (en) | 1989-05-29 |
| ATE33842T1 (de) | 1988-05-15 |
| FI80293B (fi) | 1990-01-31 |
| ES536028A0 (es) | 1986-05-16 |
| GB8423748D0 (en) | 1984-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Michaelsen et al. | Primary structure of the" hinge" region of human IgG3. Probable quadruplication of a 15-amino acid residue basic unit. | |
| Ling et al. | Isolation, primary structure, and synthesis of human hypothalamic somatocrinin: growth hormone-releasing factor. | |
| Manning et al. | The regulatory components of adenylate cyclase and transducin. A family of structurally homologous guanine nucleotide-binding proteins. | |
| Carlsen et al. | Human chorionic gonadotropin: linear amino acid sequence of the β subunit | |
| Atassi et al. | Immunochemistry of sperm whale myoglobin. I. Specific interaction of some tryptic peptides and of peptides containing all the reactive regions of the antigen | |
| Narita et al. | The amino acid sequence of cardiotoxin from Formosan cobra (Naja naja atra) venom | |
| Walker et al. | The Primary Structure of a Non‐histone Chromosomal Protein | |
| KR850002283A (ko) | 동종 면역 인터페론 단편의 제조방법 | |
| Timpl et al. | Identification of a new basement membrane collagen by the aid of a large fragment resistant to bacterial collagenase | |
| Anastasi et al. | The isolation and amino acid sequence of eledoisin, the active endecapeptide of the posterior salivary glands of Eledone | |
| Olafson et al. | Amino acid sequence of Streptomyces griseus trypsin. Cyanogen bromide fragments and complete sequence | |
| Sherwood | Similarities in the chemical structure of human placental lactogen and pituitary growth hormone. | |
| Jones et al. | Structure of two adrenal polypeptides containing multiple enkephalin sequences | |
| SCHALLY et al. | Isolation and amino acid sequence of α2-corticotropin-releasing factor (α2-CRF) from hog pituitary glands | |
| KR880009125A (ko) | 재조합 숙주에 의해 제조되는 췌장분비 트립신 억제제 및 그의 변이체, 그의 방법, 표현벡터 및 재조합 숙주 및 그의 제약상 용도 | |
| RU93045577A (ru) | Слитные полипептиды | |
| DK0479912T3 (da) | Fremgangsmåde til hæmning af N-endereglens forløb i levende celler | |
| Graf et al. | Cathepsin D generates γ-endorphin from β-endorphin | |
| Shimomura et al. | Rapid purification and characterization of human platelet glycoprotein V: the amino acid sequence contains leucine-rich repetitive modules as in glycoprotein Ib | |
| DE69030937D1 (de) | Mutanten von Interleukin-3 | |
| Li et al. | Adrenocorticotropins: XXI. The amino acid sequence of bovine adrenocorticotropin | |
| Leslie et al. | The products from papain and pepsin hydrolyses of guinea-pig immunoglobulins γ1G and γ2G | |
| KR850002285A (ko) | 면역 인터페론의 제조방법 | |
| Sternby et al. | Purification and characterization of pancreatic colipase from the dogfish (Squalus acanthius) | |
| Bosc-Bierne et al. | Isolation and partial structural characterization of chicken pancreatic colipase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application | ||
| J2X1 | Appeal (before the patent court) |
Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |